Aditya Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aditya Sharma has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Bk Thelma
Department of Genetics University of Delhi South Campus New Delhi India
4 shared publications Nidhi Jatana
3 shared publicationsJibin John
Department of Genetics, University of Delhi South Campus, Benito Juarez Road, New Delhi 110 021, India
2 shared publications- Manisha Saini
Center for Advanced Biotechnology and Medicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
2 shared publications - Suman Kundu
Department of Biochemistry, University of Delhi South Campus, New Delhi, 110021, India; Department of Biological Sciences, Birla Institute of Technology and Science Pilani, K K Birla Goa Campus, Goa, 403726, India
2 shared publications - Triptish Bhatia
Dept. of Psychiatry, Centre of Excellence in Mental Health, Atal Bihari Vajpayee Institute of Medical Sciences (ABVIMS) and Dr Ram Manohar Lohia Hospital, New Delhi, India
2 shared publications
Latest Publications
- 1 July 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (25)
Structural, Electronic Structure, and Pseudocapacitive Properties of Na‐Doped NiO Nanoparticles
Na‐doped NiO nanoparticles were synthesized using chemical precipitation method. X‐ray diffraction (XRD) patterns confirmed the single‐phase synthesis of Na:NiO. Fourier transform infrared spectroscopy (FTIR) spectra indicated an enhancement in Na─O stretching vibration with increasing Na concentrations. The specific surface areas of pure NiO, 5Na‐NiO, and 10Na‐NiO samples were found to be 4.08, 5.67, and 6.48 m 2 /g, respectively. The scanning electron microscopy (SEM) results reveal a granular morphology. Moreover, near‐edge X‐ray absorption fine structure (NEXAFS) spectra at the Ni L‐edge and O K‐edge demonstrate the existence of Ni 2 ⁺ ions and the perturbation of hybridized O 2p and Ni 3d states induced by Na doping. Further, electrochemical measurements point to the pseudocapacitive nature of Na:NiO samples, showcasing oxidation‐reduction feature‐rich cyclic voltammograms and nonlinear galvanostatic charge‐discharge (GCD) curves. High specific capacitances of ∼ 103 F/g, ∼117 F/g, and ∼132 F/g, at a scan rate of 5 mV/s, and ∼119 F/g, ∼141 F/g, and ∼153 F/g, at a current density of 1 A/g, were achieved for pure NiO, 5Na‐NiO, and 10Na‐NiO, respectively. All samples exhibited over 80% retention for 1,000 cycles. Post‐cycling XRD and SEM measurements confirmed the structural stability and elemental integrity of the compounds, suggesting their potential applications in pseudocapacitor devices.
- 1 July 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (25)
Structural, Electronic Structure, and Pseudocapacitive Properties of Na‐Doped NiO Nanoparticles
Na‐doped NiO nanoparticles were synthesized using chemical precipitation method. X‐ray diffraction (XRD) patterns confirmed the single‐phase synthesis of Na:NiO. Fourier transform infrared spectroscopy (FTIR) spectra indicated an enhancement in Na─O stretching vibration with increasing Na concentrations. The specific surface areas of pure NiO, 5Na‐NiO, and 10Na‐NiO samples were found to be 4.08, 5.67, and 6.48 m 2 /g, respectively. The scanning electron microscopy (SEM) results reveal a granular morphology. Moreover, near‐edge X‐ray absorption fine structure (NEXAFS) spectra at the Ni L‐edge and O K‐edge demonstrate the existence of Ni 2 ⁺ ions and the perturbation of hybridized O 2p and Ni 3d states induced by Na doping. Further, electrochemical measurements point to the pseudocapacitive nature of Na:NiO samples, showcasing oxidation‐reduction feature‐rich cyclic voltammograms and nonlinear galvanostatic charge‐discharge (GCD) curves. High specific capacitances of ∼ 103 F/g, ∼117 F/g, and ∼132 F/g, at a scan rate of 5 mV/s, and ∼119 F/g, ∼141 F/g, and ∼153 F/g, at a current density of 1 A/g, were achieved for pure NiO, 5Na‐NiO, and 10Na‐NiO, respectively. All samples exhibited over 80% retention for 1,000 cycles. Post‐cycling XRD and SEM measurements confirmed the structural stability and elemental integrity of the compounds, suggesting their potential applications in pseudocapacitor devices.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 25 (2) , 137-153
ARL15 and its Multiple Disease Association: Emerging Functions and Potential Therapeutic Application
ARL15 is a member of the RAS superfamily of small GTPases and is associated with several metabolic traits, including increased risk of diabetes, rheumatoid arthritis and lipid metabolism disorders. The ARL15 gene encodes for an uncharacterized small GTP binding protein. Its precise role in human physiology remains unknown, but several genetic association studies have recognized different variants in this gene to be statistically associated with numerous traits and complex diseases. Here, we provided the unique features of ARL15 small G protein, its association with varied metabolic and lifestyle diseases, its function in vesicular and lipid trafficking, and its binding partners. We outlined this protein as a promising and emerging therapeutic target to combat metabolic disorders like cardiovascular diseases, diabetes and rheumatoid arthritis. The review provides a comprehensive description of the current advancements in ARL15 research with a perspective that focused research will position this small GTPase as a viable target for the treatment of rheumatoid arthritis.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 25 (2) , 137-153
ARL15 and its Multiple Disease Association: Emerging Functions and Potential Therapeutic Application
ARL15 is a member of the RAS superfamily of small GTPases and is associated with several metabolic traits, including increased risk of diabetes, rheumatoid arthritis and lipid metabolism disorders. The ARL15 gene encodes for an uncharacterized small GTP binding protein. Its precise role in human physiology remains unknown, but several genetic association studies have recognized different variants in this gene to be statistically associated with numerous traits and complex diseases. Here, we provided the unique features of ARL15 small G protein, its association with varied metabolic and lifestyle diseases, its function in vesicular and lipid trafficking, and its binding partners. We outlined this protein as a promising and emerging therapeutic target to combat metabolic disorders like cardiovascular diseases, diabetes and rheumatoid arthritis. The review provides a comprehensive description of the current advancements in ARL15 research with a perspective that focused research will position this small GTPase as a viable target for the treatment of rheumatoid arthritis.
- Open Access
- 13 November 2023
- Published by Indian Society for Education and Environment in Indian Journal of Science and Technology
- Vol. 16 (42) , 3743-3755
Design and Analysis of Wideband PNP Sziklai Common Collector Amplifier with High Current Gain
Objective: Objective of the manuscript is to introduce a novel idea of designing a small-signal common collector (emitter follower) amplifier with user-defined PSpice model of PNP Sziklai pair. Method: A circuit simulation program is developed on the PSpice simulation platform to design and study the proposed amplifier circuit. Small-signal AC equivalent circuit analysis authenticates the proposed amplifier design and selection of biasing components. The proposed amplifier is also implemented on Cadence Virtuoso Simulation software at 180nm technology to validate the design by performing its layout and post-layout simulation. Findings: The proposed circuit gives high current gain and smaller gain fluctuations (β) due to environmental parameter variations. The effect of variation in stage current gain of Sziklai pair components is observed under different operating conditions. Equivalent circuit analysis, noise performance, and the effect of temperature on the performance of the proposed circuit are widely discussed. Other possible circuit structures with a similar concept of design are also discussed as special cases. Highly stable amplifier current gain as well as device current gain, high amplifier voltage gain, device voltage gains below unity, and low harmonic distortion are prime features of proposed circuit. The problem of finding a matched pair of BJTs for the Sziklai pair is also addressed in the proposed design. The linear distortion-less operation of this circuit, combined with its very high current gain, makes it a suitable candidate for instrumentation amplifiers with wide operating frequency range. The proposed amplifier takes up (10.105 x 10.055) μm2 of area at 180nm technology. The results of pre-layout and post-layout AC responses show that there is a close resemblance between the parameters before and after the layout, which promotes the usability and design of the proposed amplifier. Novelty: The idea explored in the manuscript is entirely new and first time announced by authors. Keywords: PNP Sziklai Pair, Common Collector Amplifier, Current Gain, Small Signal Amplifier, Cadence Virtuoso
- 13 November 2023
- Published by Indian Society for Education and Environment in Indian Journal of Science and Technology
- Vol. 16 (42) , 3743-3755
Open AccessDesign and Analysis of Wideband PNP Sziklai Common Collector Amplifier with High Current Gain
Objective: Objective of the manuscript is to introduce a novel idea of designing a small-signal common collector (emitter follower) amplifier with user-defined PSpice model of PNP Sziklai pair. Method: A circuit simulation program is developed on the PSpice simulation platform to design and study the proposed amplifier circuit. Small-signal AC equivalent circuit analysis authenticates the proposed amplifier design and selection of biasing components. The proposed amplifier is also implemented on Cadence Virtuoso Simulation software at 180nm technology to validate the design by performing its layout and post-layout simulation. Findings: The proposed circuit gives high current gain and smaller gain fluctuations (β) due to environmental parameter variations. The effect of variation in stage current gain of Sziklai pair components is observed under different operating conditions. Equivalent circuit analysis, noise performance, and the effect of temperature on the performance of the proposed circuit are widely discussed. Other possible circuit structures with a similar concept of design are also discussed as special cases. Highly stable amplifier current gain as well as device current gain, high amplifier voltage gain, device voltage gains below unity, and low harmonic distortion are prime features of proposed circuit. The problem of finding a matched pair of BJTs for the Sziklai pair is also addressed in the proposed design. The linear distortion-less operation of this circuit, combined with its very high current gain, makes it a suitable candidate for instrumentation amplifiers with wide operating frequency range. The proposed amplifier takes up (10.105 x 10.055) μm2 of area at 180nm technology. The results of pre-layout and post-layout AC responses show that there is a close resemblance between the parameters before and after the layout, which promotes the usability and design of the proposed amplifier. Novelty: The idea explored in the manuscript is entirely new and first time announced by authors. Keywords: PNP Sziklai Pair, Common Collector Amplifier, Current Gain, Small Signal Amplifier, Cadence Virtuoso
- 23 December 2020
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 40 (10) , 4626-4641
Computational insight into the three-dimensional structure of ADP ribosylation factor like protein 15, a novel susceptibility gene for rheumatoid arthritis
The ARL15 gene (ADP ribosylation factor like protein 15) encodes for an uncharacterized small GTP-binding protein. Its exact role in human physiology remains unknown, but a number of genetic association studies have recognised different variants in this gene to be statistically associated with numerous traits and complex diseases. We have previously reported a novel association of ARL15 with rheumatoid arthritis (RA) based on a genome-wide association study in a north Indian cohort. Subsequent investigations have provided leads for its involvement in RA pathophysiology, especially its potential as a novel therapeutic target. However, the absence of an experimentally determined tertiary structure for ARL15 significantly hinders the understanding of its biochemical and physiological functions, as well as development of potential lead molecules. We, therefore, aimed to derive a high quality, refined model of the three dimensional structure of human ARL15 protein using two different computational protein structure prediction methods – template-based threading and ab initio modelling. The best model each from among the five each derived from both the approaches was selected based on stringent quality assessment and refinement. Molecular dynamics simulations over long timescales revealed the ab initio model to be relatively more stable, and it marginally outperformed the template-based model in the quality assessment as well. A putative GTP-binding site was also predicted using homology for the ARL15 protein, where potential competitive inhibitors can be targeted. This high quality predicted model may provide insights to the biological role(s) of ARL15 and inform and guide further experimental, structural and biochemical characterization efforts. Communicated by Ramaswamy H. Sarma
- 23 December 2020
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 40 (10) , 4626-4641
Computational insight into the three-dimensional structure of ADP ribosylation factor like protein 15, a novel susceptibility gene for rheumatoid arthritis
The ARL15 gene (ADP ribosylation factor like protein 15) encodes for an uncharacterized small GTP-binding protein. Its exact role in human physiology remains unknown, but a number of genetic association studies have recognised different variants in this gene to be statistically associated with numerous traits and complex diseases. We have previously reported a novel association of ARL15 with rheumatoid arthritis (RA) based on a genome-wide association study in a north Indian cohort. Subsequent investigations have provided leads for its involvement in RA pathophysiology, especially its potential as a novel therapeutic target. However, the absence of an experimentally determined tertiary structure for ARL15 significantly hinders the understanding of its biochemical and physiological functions, as well as development of potential lead molecules. We, therefore, aimed to derive a high quality, refined model of the three dimensional structure of human ARL15 protein using two different computational protein structure prediction methods – template-based threading and ab initio modelling. The best model each from among the five each derived from both the approaches was selected based on stringent quality assessment and refinement. Molecular dynamics simulations over long timescales revealed the ab initio model to be relatively more stable, and it marginally outperformed the template-based model in the quality assessment as well. A putative GTP-binding site was also predicted using homology for the ARL15 protein, where potential competitive inhibitors can be targeted. This high quality predicted model may provide insights to the biological role(s) of ARL15 and inform and guide further experimental, structural and biochemical characterization efforts. Communicated by Ramaswamy H. Sarma
- 6 June 2019
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 25 (7) , 1-15
Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors
Bruton’s tyrosine kinase (BTK) is a known drug target for B cell malignancies and autoimmune diseases like rheumatoid arthritis. Consequently, efforts to develop BTK inhibitors have gained momentum in the last decade, resulting in a number of potential inhibitory molecules. However, to date, there are only two FDA approved drugs for B cell malignancies (Ibrutinib and Acalabrutinib), thus continued efforts are warranted. A large number of molecular scaffolds with potential BTK inhibitory activity are already available from these studies, and therefore we employed a ligand-based approach towards computer-aided drug design to develop a pharmacophore model for BTK inhibitors. Using over 400 molecules with known half maximal inhibitory concentrations (IC50) for BTK, a four-point pharmacophore hypothesis was derived, with two aromatic rings (R), one hydrogen bond acceptor (A) and one hydrogen bond donor (D). Screening of two small-molecule databases against this pharmacophore returned 620 hits with matching chemical features. Docking these against the ATP-binding site of the BTK kinase domain through a virtual screening workflow yielded 30 hits from which ultimately two natural compounds (two best scoring poses for each) were prioritized. Molecular dynamics simulations of these four docked complexes confirmed the stability of protein–ligand binding over a 200 ns time period, and thus their suitability for lead molecule development with further optimization and experimental testing. Of note, the pharmacophore model developed in this study would also be further useful for de novo drug design and virtual screening efforts on a larger scale. Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors
- 6 June 2019
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 25 (7) , 1-15
Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors
Bruton’s tyrosine kinase (BTK) is a known drug target for B cell malignancies and autoimmune diseases like rheumatoid arthritis. Consequently, efforts to develop BTK inhibitors have gained momentum in the last decade, resulting in a number of potential inhibitory molecules. However, to date, there are only two FDA approved drugs for B cell malignancies (Ibrutinib and Acalabrutinib), thus continued efforts are warranted. A large number of molecular scaffolds with potential BTK inhibitory activity are already available from these studies, and therefore we employed a ligand-based approach towards computer-aided drug design to develop a pharmacophore model for BTK inhibitors. Using over 400 molecules with known half maximal inhibitory concentrations (IC50) for BTK, a four-point pharmacophore hypothesis was derived, with two aromatic rings (R), one hydrogen bond acceptor (A) and one hydrogen bond donor (D). Screening of two small-molecule databases against this pharmacophore returned 620 hits with matching chemical features. Docking these against the ATP-binding site of the BTK kinase domain through a virtual screening workflow yielded 30 hits from which ultimately two natural compounds (two best scoring poses for each) were prioritized. Molecular dynamics simulations of these four docked complexes confirmed the stability of protein–ligand binding over a 200 ns time period, and thus their suitability for lead molecule development with further optimization and experimental testing. Of note, the pharmacophore model developed in this study would also be further useful for de novo drug design and virtual screening efforts on a larger scale. Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors
- 1 April 2019
- Published by Elsevier in Schizophrenia Research
- Vol. 206, 75-81
Rare variants in Protein tyrosine phosphatase, receptor type A (PTPRA) in schizophrenia: Evidence from a family based study
- 1 April 2019
- Published by Elsevier in Schizophrenia Research
- Vol. 206, 75-81
Rare variants in Protein tyrosine phosphatase, receptor type A (PTPRA) in schizophrenia: Evidence from a family based study
- Open Access
- 29 January 2018
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 45 (1) , 256-263
Rare Variants in Tissue Inhibitor of Metalloproteinase 2 as a Risk Factor for Schizophrenia: Evidence From Familial and Cohort Analysis
Candidate gene and genome-wide association study based common risk variant identification is being complemented by whole exome sequencing (WES)/whole genome sequencing based rare variant discovery in elucidation of genetic landscape of schizophrenia (SZ), a common neuropsychiatric disorder. WES findings of de novo mutations in case-parent trios have further implied genetic etiology, but do not explain the high genetic risk in general populations. Conversely, WES in multiplex families may be an insightful strategy for the identification of highly penetrant rare variants in SZ and possibly enhance our understanding of disease biology. In this study, we analyzed a 5-generation Indian family with multiple members affected with SZ by WES. We identified a rare heterozygous missense variant (NM_003255: c.506C>T; p.Pro169Leu; MAF = 0.0001) in Tissue Inhibitor of Metalloproteinase 2 (TIMP2, 17q25.3) segregating with all 6 affected individuals but not with unaffected members. Linkage analysis indicated a maximum logarithm of the odds score of 1.8, θ = 0 at this locus. The variant was predicted to be damaging by various in silico tools and also disrupt the structural integrity by molecular dynamics simulations. WES based screening of an independent SZ cohort (n = 370) identified 4 additional rare missense variants (p.Leu20Met, p.Ala26Ser, p.Lys48Arg and p. Ile217Leu) and a splice variant rs540397728 (NM_003255:c.232-5T>C), also predicted to be damaging, increasing the likelihood of contribution of this gene to SZ risk. Extensive biochemical and knockout mouse studies suggesting involvement of TIMP2 in neurodevelopmental and behavioral deficits, together with genetic evidence for TIMP2 conferring SZ risk from this study may have possible implications for new therapeutics.
- 29 January 2018
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 45 (1) , 256-263
Open AccessRare Variants in Tissue Inhibitor of Metalloproteinase 2 as a Risk Factor for Schizophrenia: Evidence From Familial and Cohort Analysis
Candidate gene and genome-wide association study based common risk variant identification is being complemented by whole exome sequencing (WES)/whole genome sequencing based rare variant discovery in elucidation of genetic landscape of schizophrenia (SZ), a common neuropsychiatric disorder. WES findings of de novo mutations in case-parent trios have further implied genetic etiology, but do not explain the high genetic risk in general populations. Conversely, WES in multiplex families may be an insightful strategy for the identification of highly penetrant rare variants in SZ and possibly enhance our understanding of disease biology. In this study, we analyzed a 5-generation Indian family with multiple members affected with SZ by WES. We identified a rare heterozygous missense variant (NM_003255: c.506C>T; p.Pro169Leu; MAF = 0.0001) in Tissue Inhibitor of Metalloproteinase 2 (TIMP2, 17q25.3) segregating with all 6 affected individuals but not with unaffected members. Linkage analysis indicated a maximum logarithm of the odds score of 1.8, θ = 0 at this locus. The variant was predicted to be damaging by various in silico tools and also disrupt the structural integrity by molecular dynamics simulations. WES based screening of an independent SZ cohort (n = 370) identified 4 additional rare missense variants (p.Leu20Met, p.Ala26Ser, p.Lys48Arg and p. Ile217Leu) and a splice variant rs540397728 (NM_003255:c.232-5T>C), also predicted to be damaging, increasing the likelihood of contribution of this gene to SZ risk. Extensive biochemical and knockout mouse studies suggesting involvement of TIMP2 in neurodevelopmental and behavioral deficits, together with genetic evidence for TIMP2 conferring SZ risk from this study may have possible implications for new therapeutics.
- 1 April 2014
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 13 (3) , 166-194
Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Catechol-O-methyltransferase (COMT) is the enzyme which catalyzes the transfer of a methyl group from S-adenosylmethionine to catechols and catecholamines, like the neurotransmitters dopamine, epinephrine and norepinephrine. COMT has implications in many neurological and psychiatric disorders like schizophrenia, Parkinson’s disease (PD), bipolar disorders, etc. and therefore, it serves as an important drug target. Since its characterization in 1957, many inhibitors were designed where the first generation inhibitors were found to be highly toxic, short acting and had poor bioavailability. Currently, two of the second generation inhibitors, tolcapone and entacapone have been used for treatment of PD but are associated with various dopaminergic and gastro-intestinal side-effects. There have been several approaches for the design of novel COMT inhibitors with a good and safe therapeutic profile. The focus of this article is to review the current knowledge on COMT and the role of COMT inhibitors in the treatment of neurological disorders. The inhibitors have been classified into six different classes based on the structural framework. A historical overview of the discovery and development of COMT inhibitors is presented with a special emphasis on new generation of inhibitors till date.
- 1 April 2014
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 13 (3) , 166-194
Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Catechol-O-methyltransferase (COMT) is the enzyme which catalyzes the transfer of a methyl group from S-adenosylmethionine to catechols and catecholamines, like the neurotransmitters dopamine, epinephrine and norepinephrine. COMT has implications in many neurological and psychiatric disorders like schizophrenia, Parkinson’s disease (PD), bipolar disorders, etc. and therefore, it serves as an important drug target. Since its characterization in 1957, many inhibitors were designed where the first generation inhibitors were found to be highly toxic, short acting and had poor bioavailability. Currently, two of the second generation inhibitors, tolcapone and entacapone have been used for treatment of PD but are associated with various dopaminergic and gastro-intestinal side-effects. There have been several approaches for the design of novel COMT inhibitors with a good and safe therapeutic profile. The focus of this article is to review the current knowledge on COMT and the role of COMT inhibitors in the treatment of neurological disorders. The inhibitors have been classified into six different classes based on the structural framework. A historical overview of the discovery and development of COMT inhibitors is presented with a special emphasis on new generation of inhibitors till date.
- 1 February 2013
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 39, 145-164
Pharmacophore modeling and virtual screening studies to design potential COMT inhibitors as new leads
- 1 February 2013
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 39, 145-164
Pharmacophore modeling and virtual screening studies to design potential COMT inhibitors as new leads
- 1 November 2012
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 57, 185-195
Identification of potential drug targets in Yersinia pestis using metabolic pathway analysis: MurE ligase as a case study
- 1 November 2012
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 57, 185-195
Identification of potential drug targets in Yersinia pestis using metabolic pathway analysis: MurE ligase as a case study